Sike Esther Mbonde Mouangue, Dimitrios Deligkas, Dimitrios Vogdos, Maria Mainou, Euthimia Vlachaki
Cutaneous infiltrates in CLL patients are a rare manifestation with unclear prognostic significance, typically occurring after diagnosis, as in our case. New therapies for CLL, such as BCL2 inhibitors, not only offer more effective disease control but also appear to help manage associated cutaneous infiltrates, as in our patient.
INTRODUCTION: Chronic lymphocytic leukemia (CLL) is a malignancy of mature CD5+ B-lymphocytes. While it typically involves the peripheral blood, bone marrow, lymph nodes, and spleen, cutaneous infiltration - leukemia cutis - is a rare manifestation of the disease, causing aesthetic problem to the patients.
CASE PRESENTATION: A 60-year-old man with a 2-year history of CLL presented with a scalp plaque. Biopsy confirmed leukemic skin infiltration. The patient was started on obinutuzumab and venetoclax. Following an infusion reaction, venetoclax monotherapy was continued, leading to rapid improvement.
CONCLUSION: Cutaneous infiltrates in CLL patients are a rare manifestation with unclear prognostic significance, typically occurring after diagnosis, as in our case. New therapies for CLL, such as BCL2 inhibitors, not only offer more effective disease control but also appear to help manage associated cutaneous infiltrates, as in our patient.